Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.

Disclaimer: This website is intended to provide information to an international audience outside the USA and UK. It contains information on LIXIANA® (edoxaban), which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission.

Disclaimer: This website is intended to provide information to an international audience outside the USA and UK. It contains information on LIXIANA® (edoxaban), which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission.

LIXIANA® (EDOXABAN) FOR THE PRESS

Welcome to the LIXIANA® press portal, where you get access to latest news, press releases, media backgrounders, images and videos for European media. For United States members of the Press, please click here to visit DSI.com. Please click here to reach the global Daiichi Sankyo press portal.

By visiting you agree you are a member of the Press, and agree to the data collection policies stated in the website Terms of Use.

You are now leaving this site. Please note that the terms of use ("Privacy Statement and Imprint") are no longer valid as soon as you click on the "Visit Site" button. Daiichi Sankyo does not have any influence on linked websites and assumes no liability for their content. If you would like to stay on this site, please click on the "Stay on LIXIANA® International Site" button.

You are now leaving this site. Please note that the terms of use ("Privacy Statement and Imprint") may change when you click on the "Visit Daiichi Sankyo Site" button. If you would like to stay on this site, please click on the "Stay on LIXIANA® International Site" button.